Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

JAMA Oncol. 2018 Jan 1;4(1):126-128. doi: 10.1001/jamaoncol.2017.3462.

Abstract

This study uses data from the National Cancer Database to examine the population-level efficacy of novel therapies for advanced-stage melanoma.

MeSH terms

  • Aged
  • Antibodies, Monoclonal* / classification
  • Antibodies, Monoclonal* / therapeutic use
  • Cell Cycle Checkpoints* / drug effects
  • Cell Cycle Checkpoints* / immunology
  • Female
  • Humans
  • Immunotherapy / methods*
  • Ipilimumab / therapeutic use
  • Male
  • Melanoma / drug therapy*
  • Melanoma / mortality
  • Melanoma / pathology
  • Middle Aged
  • Molecular Targeted Therapy / methods*
  • Neoplasm Staging
  • Protein Kinase Inhibitors* / classification
  • Protein Kinase Inhibitors* / therapeutic use
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / mortality
  • Skin Neoplasms / pathology
  • Survival Analysis
  • Treatment Outcome
  • United States / epidemiology
  • Vemurafenib / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Ipilimumab
  • Protein Kinase Inhibitors
  • Vemurafenib